A spice master in New York has a new and unusual clientele: people whose sense of taste has gone quiet. They call it ‘Ozempic tongue,’ and an entire corner of the food world is now reorganizing itself around a smaller, duller appetite — one small, intensely flavored plate at a time.
The scale is why chefs are paying attention. GLP-1 use for weight loss jumped from 3% to 11% of Americans in two years, and users report smaller appetites and flatter flavor. So the response is more intensity per bite: bolder spice, smaller portions, a plate engineered to land in fewer forkfuls.
It is a small story with a giant lesson attached. Ask anyone who owned a packaged-food name how fast a demand curve moves when the underlying behavior changes — and this one changed in 24 months.
Here is the part worth saying plainly for the book. A single class of drug rewrote a demand curve in twenty-four months, and ‘defensive consumer staple’ quietly stopped being a synonym for ‘safe.’ It is exactly why the staples we hold are the ones with pricing power and portfolios nimble enough to reformulate the plate — the shelf is far less stable than its reputation. When behavior can shift this fast, the moat is adaptability, not shelf space, and we underwrite the companies that can change the recipe.
No trade, a lens. When a drug reorganizes an entire consumer category in two years, ‘defensive staple’ stops being a synonym for ‘safe.’ It is exactly why the staples we hold are the ones with pricing power and adaptable portfolios — the shelf is not as stable as it looks, and the flavor of demand can change overnight.